Sareum Holdings plc (AIM:SAR)

London flag London · Delayed Price · Currency is GBP · Price in GBX
14.11
-0.89 (-5.96%)
Nov 7, 2025, 4:25 PM GMT+1
-5.96%
Market Cap20.02M
Revenue (ttm)n/a
Net Income (ttm)-2.96M
Shares Out138.07M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume181,889
Average Volume531,425
Open14.50
Previous Close15.00
Day's Range14.11 - 16.00
52-Week Range9.00 - 29.00
Beta-0.87
RSI38.25
Earnings DateMar 20, 2026

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also involves in developing SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor, which h... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 5
Stock Exchange London Stock Exchange AIM
Ticker Symbol SAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.